Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda, Sanford-Burnham Ink Obesity Discovery Deal To Explore Non-CNS Options

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical Co. Ltd. and the Sanford-Burnham Medical Research Institute have formed a collaboration focused on identifying and validating new targets and pathways outside of the central nervous system for treating obesity

You may also be interested in...



More Obesity Setbacks For Amylin And Takeda

Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field

More Obesity Setbacks For Amylin And Takeda

Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field

More Obesity Setbacks For Amylin And Takeda

A Phase II trial for their Symlin-based combination therapy was halted after safety issues cropped up with patients from a previous study.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel